Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06458049
Other study ID # 21-697
Secondary ID R21CA279278
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date September 2024
Est. completion date May 31, 2027

Study information

Verified date June 2024
Source Dana-Farber Cancer Institute
Contact Sharon Bober, PhD
Phone 617-632-6547
Email sharon_bober@dfci.harvard.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

SHAREonline is a study for young female cancer survivors that are experiencing changes in sexual health and function. The purpose of this research is to compare two brief interventions delivered by videoconference to learn if they help women effectively manage these changes and restore sexual health and functioning.


Description:

The purpose of this research is to compare two brief interventions delivered by videoconference to learn if they help women effectively manage these changes and restore sexual health and functioning. Participants in this study would first complete health questionnaires and then be randomized to take part in one of two types of education sessions delivered by an instructor over videoconference: 1) Group education session or 2) Individual self-management session. About 56 women will receive the group education session and about 28 will receive the individual self-management session. It is expected that about 84 women will take part in this study.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 84
Est. completion date May 31, 2027
Est. primary completion date May 31, 2027
Accepts healthy volunteers No
Gender Female
Age group 19 Years to 49 Years
Eligibility - Female cancer survivors age 19-49 - Cancer diagnosis (except non-melanoma skin cancer) = 1 year prior - Diagnosed with first cancer = age 18 - No active cancer therapy (excluding chemoprevention) in the past four months, and no further therapy planned - Ability to read and write in English - Bothered by significant sexual dysfunction as evidenced by a Female Sexual Functioning Index (FSFI) score of =26. - Regular access to the internet Exclusion Criteria - Has never been sexually active - Any impairment (e.g., hearing, visual, cognitive) that interferes with the ability to complete all study procedures independently

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Group Session
On-line educational session-3 modules-1 hour each for a total of 3 hours
Coaching Call
Single Coaching phone call at one month
Educational Materials
Individual videoconference session in which participants will receive a pdf of the American Cancer Society booklet, 'Sex and the Adult Female with Cancer

Locations

Country Name City State
United States Dana Farber Cancer Institute Boston Massachusetts

Sponsors (2)

Lead Sponsor Collaborator
Dana-Farber Cancer Institute National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Sexual Self-efficacy Sexual Self-Efficacy Scale is a 5-item scale developed to measure perceived sexual self-efficacy to address sexual health after cancer. Baseline to 2 months
Other Sexual Self-efficacy Sexual Self-Efficacy Scale is a 5-item scale developed to measure perceived sexual self-efficacy to address sexual health after cancer. Baseline to 4 months
Other Coaching Satisfaction Summary Brief participant questionnaire to provide feedback about coaching session. Up to 1 month post-coaching session
Primary Change in Sexual Function The Female Sexual Function Index (FSFI Full Scale Score), is 19-item instrument which measures sexual function, including desire, orgasm, pain and satisfaction. Baseline to 2 months
Secondary Change in Emotional Distress BSI-18 (Brief Symptom Inventory) The BSI-18 is a well-validated screening measure of psychological distress with subscales measuring anxiety, depression and somatization that is frequently used with oncology populations. Baseline to 2 month
Secondary Change in Sexual Function The Female Sexual Function Index (FSFI Full Scale Score), is 19-item instrument which measures sexual function, including desire, orgasm, pain and satisfaction. Baseline to 4 months
Secondary Change in Emotional Distress BSI-18 (Brief Symptom Inventory) The BSI-18 is a well-validated screening measure of psychological distress with subscales measuring anxiety, depression and somatization that is frequently used with oncology populations. Baseline to 4 months
Secondary Enrollment Rate Measured through study accrual with a benchmark of enrollment greater than or equal to 40% of eligible candidates Baseline to 1 month
Secondary Intervention Acceptability Rate Intervention Satisfaction Questionnaire will be assessed using a benchmark mean score of 4 Up to 1 month-post intervention
Secondary Study Engagement Rate Measured through study engagement with a benchmark of study engagement greater than or equal to 70% of eligible candidates Baseline to 1 month
Secondary Intervention Completion Rate Measured through intervention completion with a benchmark of intervention completion greater than or equal to 60% of eligible candidates Baseline to 4 months
Secondary Distress about Sexual Function Sexual Distress Scale-short form (SDS-SF) is a 5-item measure which assesses distress about sexual function. Baseline to 2 months
Secondary Distress about Sexual Function Sexual Distress Scale-short form (SDS-SF) is a 5-item measure which assesses distress about sexual function. Baseline to 4 months
Secondary Sexual Function, Satisfaction and Sexual Inactivity PROMIS Sexual Function and Satisfaction (PROMIS SexFS) is a short screening Baseline to 2 months
See also
  Status Clinical Trial Phase
Terminated NCT05072158 - Pelvic Floor Disorders Among Sexual Minoritized Women
Recruiting NCT05312320 - Improving Sexual Function After Myocardial Infarction N/A
Completed NCT05561972 - The Ultrasonographic Assessment of Efficacy of Injectable Hyaluronic Acid for Genitourinary Syndrome of Menopause N/A
Completed NCT03943485 - Utilization of Uterine Manipulator in Abdominal Hysterectomy N/A
Completed NCT06231433 - Effects of Fractional CO2 Laser Treatment on Vaginal Symptoms and Sexual Dysfunction in Women With Systemic Sclerosis Phase 2/Phase 3
Recruiting NCT05698576 - TRANBERG® Transperineal MR/US Fusion Laser--Induced Thermal Therapy for Men With Prostate Cancer N/A
Recruiting NCT06028009 - PRP Injections for Genitourinary Syndrome of Menopause N/A
Not yet recruiting NCT06017128 - Sexual Counseling's Impact on Hip Replacement Patients' Sexual Function and Quality of Life: A PLISSIT Model Study N/A
Completed NCT04420533 - Comparative Study Between Behavior Therapy and Behavior Therapy Plus Mirabegron in Sexually Active Men With OAB Symptoms N/A
Completed NCT05964608 - The Effect of Behavioral Therapy Given to Men and Their Partners' N/A
Completed NCT03194997 - Pilates and Dance to Breast Cancer Patients Undergoing Treatment N/A
Completed NCT04752241 - Preservation of Inferior Mesenteric Artery Could Improve Sexual Function After Laparoscopic Colorectal Resection for Diverticular Disease N/A
Completed NCT05707429 - Sexual Function and Quality of Life Among Patients Suffering From Inflammatory Bowel Disease(Inactive Stage)
Completed NCT04923217 - Quality of Life and Sexual Function in Vaginal Aplasia Patients After Davydov Procedure
Completed NCT03571841 - Sexual Health and Rehabilitation After Ovarian Suppression Treatment N/A
Recruiting NCT05342090 - Postoperative Return to Sexual Activity N/A
Recruiting NCT03087565 - Urinary and Sexual Functions After Subtotal Versus Total Abdominal Hysterectomy N/A